The neural mobilization technique modulates the expression of endogenous opioids in the periaqueductal gray and improves muscle strength and mobility in rats with neuropathic pain by Santos, Fabio Martinez et al.
  Universidade de São Paulo
 
2014
 
The neural mobilization technique modulates
the expression of endogenous opioids in the
periaqueductal gray and improves muscle
strength and mobility in rats with neuropathic
pain
 
 
Behavioral and Brain Functions. 2014 May 13;10(1):19
http://www.producao.usp.br/handle/BDPI/47255
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Anatomia - ICB/BMA Artigos e Materiais de Revistas Científicas - ICB/BMA
RESEARCH Open Access
The neural mobilization technique modulates the
expression of endogenous opioids in the
periaqueductal gray and improves muscle
strength and mobility in rats with neuropathic
pain
Fabio Martinez Santos1,2,3,4, Leandro Henrique Grecco2, Marcelo Gomes Pereira3, Mara Evany Oliveira1,
Priscila Abreu Rocha1, Joyce Teixeira Silva1, Daniel Oliveira Martins1, Elen Haruka Miyabara3 and Marucia Chacur1*
Abstract
Background: The neural mobilization (NM) technique is a noninvasive method that has been proven to be
clinically effective in reducing pain; however, the molecular mechanisms involved remain poorly understood. The
aim of this study was to analyze whether NM alters the expression of the mu-opioid receptor (MOR), the delta-opioid
receptor (DOR) and the Kappa-opioid receptor (KOR) in the periaqueductal gray (PAG) and improves locomotion and
muscle force after chronic constriction injury (CCI) in rats.
Methods: The CCI was imposed on adult male rats followed by 10 sessions of NM every other day, starting 14 days
after the CCI injury. At the end of the sessions, the PAG was analyzed using Western blot assays for opioid receptors.
Locomotion was analyzed by the Sciatic functional index (SFI), and muscle force was analyzed by the BIOPAC system.
Results: An improvement in locomotion was observed in animals treated with NM compared with injured animals.
Animals treated with NM showed an increase in maximal tetanic force of the tibialis anterior muscle of 172%
(p < 0.001) compared with the CCI group. We also observed a decrease of 53% (p < 0.001) and 23% (p < 0.05) in DOR
and KOR levels, respectively, after CCI injury compared to those from naive animals and an increase of 17% (p < 0.05) in
KOR expression only after NM treatment compared to naive animals. There were no significant changes in MOR
expression in the PAG.
Conclusion: These data provide evidence that a non-pharmacological NM technique facilitates pain relief by
endogenous analgesic modulation.
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Background
Injury to the peripheral nervous system (PNS) and the
spinal cord contributes to the development of peripheral
neuropathy; this damage then triggers ectopic focus in
peripheral nerve fibers, which maintain continuous im-
pulses to the central nervous system (CNS). These events,
which are associated with central sensitization in the pres-
ence of peripheral nerve injury, contribute to the develop-
ment of neuropathic pain [1,2]. Thus, injuries in any part
of the course of this nerve can cause changes in sensory
and motor structures involved in the area of innervation
[3]. Studies have demonstrated that sciatic nerve in-
jury in an animal model that is induced by chronic
constriction injury (CCI) causes autonomic and motor
changes, such as dystonic posturing and changes in
locomotion [4]. It has been extensively reported that
neuropathic pain is difficult to treat in clinical practice
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due to poor understanding of the cellular and molecular
mechanisms involved in the development and mainten-
ance of this type of pain [5,6]. Evidence suggests the in-
volvement of opioid supraspinal regions in rats with
neuropathic pain induced by CCI [7].
Opioids are potent analgesics that exert pharmacolo-
gical and physiological effects through interactions with
receptors distributed in several regions. Three subtypes
of opioid receptors are known: MOR (μ), DOR (δ) and
KOR (k). These subtypes are widely distributed in vari-
ous systems, such as the immune, pituitary-adrenal axis,
peripheral and central nervous systems, and they are im-
portant regulators of pain and inflammation [8,9]. Opioid
peptides and their receptors are involved in a multitude of
functions in the CNS, including stress, anxiety and antino-
ciception [10]. In the peripheral nervous system, the re-
ceptors MOR, DOR and KOR are also found in the
posterior root ganglion [11,12]. The first clues regarding
the role of these receptors in peripheral analgesia ap-
peared in 1987; the activation of opioid receptors were
shown to reduce hyperalgesia, suggesting a decrease in
spontaneous discharge of the fibers from C-type primary
afferent neurons [13-15]. Between 1970–1980, it was hy-
pothesized that the involvement of brain regions in the
modulation of nociceptive primary afferent inputs origi-
nated from the peripheral nervous system [16]. Evidence
indicated that electrical stimulation of the periaqueductal
gray (PAG) induces intense analgesia in rats [16]. The
PAG anatomically comprises a number of columns ori-
ented in a longitudinal neuronal rostrocaudal direction,
for example, the column dorsomedial (dm), the dorso-
lateral column (dl), the column lateral (Lat), the medial
column (m) and the ventrolateral pillar (VL) [17]. The col-
umn of the ventrolateral PAG was thought to be the main
region responsible for the release of endogenous opioids
[18]; this region was examined to understand the relation-
ship of the descending pain inhibitory system (endogenous
opioids) on primary afferent nociceptive C fibers [19]. In
addition, the PAG is responsible for the projection of
neuron groups in the region of the rostral ventromedial
medulla (RVM), where the nuclei raphe magnus, giganto-
cellular reticular nucleus and lateral gigantocellular are
found [20]. Thus, the retransmission pulses coming from
the PAG to the RVM are relayed to the spinal cord
via the dorsolateral funiculus (LDF) causing attenu-
ation of primary nociceptive stimuli by activating OFF
cells (GABAergic) and inhibiting ON cells [21]; this is
also the location where opioids and substance P play
a fundamental role in the direct and indirect control
over the descending modulation of pain [22].
The neural mobilization (NM) technique is a noninvasive
physiotherapy method that has been proven to be clinically
effective in reducing pain sensitivity after neuropathic
pain [23]. Furthermore, Lopes et al. [24] demonstrated in
humans that the NM technique can cause increased mus-
cle strength of the quadriceps muscle that may be associ-
ated with improved axoplasmic flow. Furthermore, when
applied in rats with neuropathic pain, the NM technique
can regenerate the sciatic nerve by increasing the expres-
sion of zero nerve growth factor [25].
The current study tests the hypothesis that the NM
technique reverses neuropathic pain by enhancing endo-
genous opioid-mediated pain modulatory systems. This
hypothesis was evaluated by behavioral tests and Western
blotting assays of the periaqueductal gray of adult neuro-
pathic rats before and after treatment with NM.
Methods
Animals
Male Wistar rats, weighing between 180 and 220 g (ap-
proximately 2 months old), were used in all experiments.
The rats were singly housed and maintained on a 12:12 h
light/dark cycle and were adapted to the experimental en-
vironment three days before the experiments started. All
animals were tested during the light cycle at the same time
of the day (9:00 a.m. – 12:00 p.m.). All procedures were
approved by the Institutional Animal Care Committee of
the University of São Paulo (protocol number 091 – book
number 02/2012) and performed in accordance with the
guidelines for the ethical use of conscious animals in pain
research published by the International Association for
the Study of Pain [26].
Surgical procedure
Chronic constriction injury - (CCI)
For the induction of neuropathic pain, chronic constric-
tion of the sciatic nerve was performed as previously de-
scribed by Bennett and Xie in [4]. In short, rats were
anesthetized with halothane (Cristalia, Brazil) [4]. The
common sciatic nerve was exposed at the level of the
middle of the thigh by blunt dissection through the bi-
ceps femoris. Proximal to the sciatic trifurcation (about
7 mm), the nerve was freed of adhering tissue, and 4 lig-
atures (4.0 chromic gut) were tied loosely around it with
approximately 1 mm spacing. Great care was taken to
tie the ligatures such that the diameter of the nerve was
seen to be just barely constricted. The incision was
closed in layers. In sham-operated rats, the same inci-
sion was made, as described above, the sciatic nerve was
exposed at the same level but left unaffected, and the
muscle was sutured. This animals was used as a control.
Each rat was closely observed during the recovery from
anesthesia and then returned to the home cage and care-
fully observed during the following 24 hours. During the
5 day-period after CCI, walking and cage exploration,
the degree of limping, and the conditions of the hind-
paw, including signs of excessive grooming or autotomy,
were all closely observed.
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Sciatic functional index (SFI)
The SFI was then measured under normal conditions,
14 days after nerve injury, as well as the third, seventh
and tenth sessions of the neural mobilization and sham
procedures. We used a total of 5 animals for each group.
To evaluate the functional activity, the sciatic functional
index, which evaluates the footprints of animals, was
used [27]. The footprints of the animals were obtained
by the method proposed by De Medinaceli et al. [27,28]
using paper strips impregnated with blue bromofenols.
A walkway (44 cm × 8.7 cm) was constructed in wood
according to De Medinaceli et al. [27,28] and closed on
the sides; a hutch was provided at the end where the
animal could find shelter and food pellets after traveling
throughout its length [28,29]. The animals were trained
to walk on the runway prior to the initial steps and were
considered fit if they crossed the footbridge (e.g., the
initial opening to the hutch) without hesitation. Once
trained, the initial steps were performed with the ani-
mals walking with their hind legs moistened with water
on the dyed leaves. Based on the footprints obtained, the
following parameters were measured (using a MARK –
MYTUTOYO caliper): (1) print length, (2) spread of the
toes, and (3) intermediate toes. These data were collec-
ted on the normal side (non-operated) (NPL, NTS and
NIT) and the experimental side (operated) (EPL, ETS
and EIT). The data were analyzed using the equation de-
veloped by De Medinaceli et al. [27] and adapted by Bain
et al. (1989) and Hare et al. (1992): SFI = − 38.3 × [(EPL −
NPL)/NPL] + 109.5 × [(ETS −NTS)/NTS] + 13.3 × [(EIT −
NIT)/NIT] − 8.8. Where: N = normal; E = Experimental;
PL = print length; TS = spread of toes; IT = intermediate
toes [30,31]. The results obtained from this equation are
expressed in a negative percentage of normal function,
where 0 (zero) (standard deviation of −11 to 11) corre-
sponds to normal function or no disability, and −100
(minus one hundred) correspond to full dysfunction.
In vivo muscle function experiments
Based on Pereira et al. [32] rats were anesthetized with
tribromoethanol (20 mg/100 g BW, i.p.). The exposition
of their sciatic nerves was performed through a lateral
incision on the thigh, and an electrode was coupled. The
innervations of the sciatic nerve to the tibialis anterior
muscle were cautiously isolated from those originated
from other nerves. Then, the animals were placed on an
acrylic platform with a metallic bar crossing their knees
to fix their limbs. The tibialis anterior tendon was con-
nected to a force transducer coupled to a computer that
was used to assemble and analyze force generated by the
muscle contraction [32]. Muscle twitch and tetanic forces
were documented using the Biopac Systems (Goleta©, CA,
USA). Muscle strength was analyzed using the software
AcqKnowledge 3.9.1.6. Rats were submitted to external
warming in order to maintain their core temperature
throughout the procedure.
At the start of the experiment, the muscle was set to
the optimum length (L0, defined as a length resulting in
maximum twitch force) and a two-minute rest period
was applied between stimuli (data not shown). In order
to achieve the maximal plateau force with minimal fre-
quency, we used 200Hz stimuli for measuring the max-
imal tetanic force.
Based on Chan and Head (2010), isolated twitches
(0.2Hz) were generated over a 2-min period, followed by
a maximum tetanic contraction (induced for 2-s) in each
muscle (at 200Hz) [33]. We observed no differences in
terms of twitch parameters, such as the time-to-peak
and half-relaxation time (data not shown). The results
were expressed as maximum tetanic force.
Neural mobilization (NM) technique
The NM technique used here has been described by Butler
(1989) and adapted by our laboratory [23,34]. Briefly, rats
were anesthetized with isoflurane, with a continuous flow
of medicinal oxygen throughout the procedure (5 ml/L –
0, 5%/L). After anesthesia, the animals were positioned in
the left lateral position to mobilize the right side (ipsilateral
to the CCI). The right knee joint was then positioned in
full extension (at 0 degrees) and remained so throughout
the session. Moreover, the right hip joint was bent between
70 to 80 degrees with the knee in extension until a small
resistance was induced by stretching the muscles from the
compartimentum posterius femoris (biceps m., femoris m.,
semimembranosus m., and semitendinosus m.). After the
manipulator felt the resistance, the angle of the joint was
interrupted. At this time, the ankle joint was angled be-
tween 30 to 45 degrees, using the same principle described
above. After all of the joints were positioned with minimal
resistance of those muscles, oscillatory movements were
initiated. The right ankle joint was manipulated in dorsi-
flexion (30 to 45 degrees) at approximately 20 oscillations
per minute for 2 minutes, followed by a 25-second pause
for rest. The treatment was performed for ten minutes; in
the last minute, the cervical spine was fully flexed with the
purpose of tensioning the entire neuraxis [35]. Treatment
with the NM technique started 14 days after the injury or
sham procedure, and the NM sessions were conducted
every other day for a total of 10 sessions. The animals was
divided in 5 groups, naive, CCI, CCINM, Sham and
ShamNM, we used a total of 5 animal in each group, after
the last NM sessions, animals were sacrificed for immuno-
blotting and in vivo muscle experiments as described
below and above respectively.
Immunoblotting
Western blotting analyses were performed on samples
from individual animals. Neuropathic (CCI), sham and
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naive rats were sacrificed by decapitation under isofluor-
ane anesthesia, and the PAG was quickly removed and
homogenized in an extraction buffer containing 100 mM
Tris, pH 7.4, 10 mM EDTA, 2 mM PMSF, and 10 μg/mL
aprotinin. After extraction, the homogenates were cen-
trifuged at 11,500 × g for 20 min, and the protein con-
centration of the supernatant was determined using
the Bradford protein assay with albumin as a standard
(Bio-Rad, USA) [36]. Samples containing 75 μg protein
were loaded on a 12% acrylamide gel and electrotrans-
ferred to nitrocellulose membranes using a Bio-Rad mini-
ature transfer apparatus for 1.5 h at 120 V. After transfer,
the membranes were treated for 2 h at room temperature
with a blocking solution containing 5% powdered milk,
washed and incubated overnight at 4°C with rat monoclo-
nal antibodies against Anti-MOR or (μ), DOR or (δ) or
KOR or (k) (all 1:250 – Santa Cruz Biotechnology, INC)
[37-39]. Membranes were then washed and incubated for
2 h at room temperature with a peroxidase-conjugated,
goat anti-rabbit secondary antibody (to MOR and DOR)
diluted 1:5000 (Jackson ImunuResearch, Laboratories,
INC) and a donkey anti-goat (to KOR) secondary antibody
diluted 1:5000 (Jackson ImunuResearch, Laboratories,
INC). In all immunoblotting experiments, β-actin (mouse,
1:15000; Sigma-Aldrich, USA) was used as an internal
control. The specific antibody bind was visualized using a
chemoluminescence kit (Amersham Biosciences). The blot
was densitometrically analyzed using NIH-Scion Image
4.0.2 (Scion Corporation, USA).
Statistical analysis
Results are presented as the mean ± SEM. The data were
analyzed using GraphPAD Prism, version 4.02 (Graph-
Pad Software Inc., San Diego, CA). Statistical compari-
son of more than 2 groups was performed using analysis
of variance (ANOVA); differences between means were
determined by Tukey's multiple comparison test when
appropriate. In all cases, p < 0.05 was considered statisti-
cally significant [40].
Results
Assessment of locomotor function through the sciatic
functional index (SFI)
Initially, all animals were tested for the sciatic functional
index to evaluate the response of locomotion and to ob-
tain the initial measures (BL - baseline). On the four-
teenth day after injury, all animals were re-evaluated to
check for possible changes in the SFI. In this period,
the animals in groups CCI and CCI NM partially unloa-
ded body weight on the right leg (injured), reflecting in
complete adduction of their fingers and sagging. These
changes were represented by a decrease in SFI values
compared with baseline measures and control groups:
Sham (Sham and Sham NM) and naive groups showed no
changes in SFI values. It is worth mentioning that the ob-
served decrease in the SFI in the CCI group remained
during all evaluation measures of locomotion until the
date of euthanasia (Figure 1). It is essential to highlight
that the dysfunction in ambulation was characterized by
damage in the sciatic nerve (CCI).
When the animals from the CCI NM group were sub-
mitted to the SFI tests 14 days after surgery, the same
signal from the CCI group was observed (e.g., partial
discharge of body weight on the right leg (op) reflecting
incomplete adduction of the fingers and sagging). How-
ever, during treatment with NM, the animals showed an
increase to values close to zero at the SFI, representing
an improvement of locomotion. Both the Sham (Sham
and Sham NM) and naive control groups remained at
values close to the initial measures without significant
changes (Figure 1). The changes observed between groups
CCI and CCI NM reflect the improvement caused by the
NM technique, demonstrating a beneficial effect of this
technique on motor dysfunction caused by chronic con-
striction injury of the sciatic nerve.
In vivo muscle function experiments
Our results showed that the maximal tetanic force of the
tibialis anterior muscle from the CCI group decreased
by 52% (p < 0,001) compared to the naive group. How-
ever, muscles from the CCI NM group showed an increase
of maximal tetanic force of 172% (p < 0,001) compared to
the CCI group and a decrease of 10% compared to the
naive group (Figure 2). No difference in maximal tetanic
contraction was observed between the Sham groups and
the naive group.
Figure 1 Analysis of Sciatic Functional Index (SFI). Motor
dysfunction was induced by chronic constriction injury (CCI) to the
sciatic nerve. Functional assessment was evaluated, 14 days after
injury (14d PO), after the third (3°s); seventh (7°s); and tenth (10°s)
session (s) using the SFI. The results obtained are expressed as a
percentage of normal function, where 0 (zero) corresponds to
normal function or no disability and −100 (minus one hundred)
corresponds to total dysfunction. The results are expressed as the
mean ± S.E.M. Five animals per group. *p <0.05 per CCI comparison
group. #p <0.05 compared to the CCI NM group and p <0.05
compared to the initial measurement.
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Effects of NM on the expression of opioid receptors in the
periaqueductal gray
We employed analysis of the DOR, MOR and KOR pro-
tein expression levels to evaluate how CCI and NM treat-
ment can alter opioid protein levels.
Our results showed a decrease of 53% (p < 0.001) in
DOR levels after CCI injury compared to those from naive
animals and a return to basal levels after NM treatment.
The difference between the CCI NM and CCI groups was
approximately 50% (p < 0.001) (Figure 3A).
Regarding KOR protein expression, we observed a de-
crease of 23% (p < 0.05) in KOR levels after CCI injury
compared to naive animals and an increase of 17% in
KOR expression after NM treatment (p < 0,05). The dif-
ference between the CCI NM and CCI groups was ap-
proximately 40% (p < 0.01) (Figure 3B).
No differences in MOR expression between the groups
were observed when the periaqueductal gray was ana-
lyzed (Figure 3C).
No difference was observed between the naive and
sham-NM groups or between the sham and sham-NM
groups (data not show). No difference was observed in
the β-actin expression between control and experimental
sides at all time points tested (Figure 3).
Discussion
The NM technique reversed the deficit in muscle strength
and locomotor dysfunction observed in the CCI mo-
del of induced neuropathic pain. Moreover, this non-
pharmacological therapy increased the expression of
opioid receptors, especially the DOR and KOR in the
PAG, suggesting that these effects may occur through
activation of endogenous opioid-mediated pain modu-
latory systems.
Figure 2 Analysis of in vivo muscle function experiments. The
results are expressed in grams. The results are expressed as the
mean ± S.E.M. n = 5. **p <0.001 comparing the CCI and control
groups (naive, sham and sham NM) *p <0.001 comparing the CCI
NM and CCI groups.
Figure 3 Densitometry analysis of DOR (A), KOR (B) and MOR (C) expression in the periaqueductal gray after CCI injury. The normalized
average between sham and experimental groups (CCI) is reported. Values measured for naive animals were considered 100%. Data are reported
as the mean ± SEM of 6 animals per group. A) *p < 0.001 comparing the CCI group with the naive group. B) *p < 0.05 the CCI group with naive
animals, **p < 0.001 comparing the CCI NM group with the other groups.
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Regarding the lack of MOR opioid receptors be involved
in our model is intriguing. Different studies showed dis-
tinct results regarding different type of opioid receptor.
Konno et al. [41] showed the involvement of KOR opioid
receptors in the antinociceptive effect induced by a pep-
tide in the nociceptive effect by prostaglandin E2 and car-
rageenin [41]. In addition, other studies also demonstrated
difference in opioid expression; studies showed an involve-
ment of only KOR and DOR opioids receptors in a cancer
pain model [42] and in a crude crotalic venom model
[43], both authors do not observed the involvement of
MOR opioid receptors in their models.
Also, studies showed that opioid receptor expression is
distinctly regulated by the presence of acute or chronic
injury, as prostaglandin E2 increases the expression and
activity (by the selective agonists) of MOR and KOR-
opioid receptors in rat DRG and nerve paw and decreases
the expression and activity of DOR-opioid receptors. In
contrast, chronic constriction injury of sciatic nerve up-
regulates DOR-opioid receptors [44].
Opioids receptors are expressed in brain regions that
modulate nociception, including anterior cingulated cor-
tex, thalamus and periaqueductal grey (PAG) [45]. These
areas have anatomical connections and involvement in
establishment chronic pain states [7].
This hypothesis was confirmed by previous works de-
monstrating that analgesia by noninvasive techniques is
mediated via neuronal mechanisms correlated with the
central nervous system, with endogenous opiates and de-
scending inhibitory mechanisms being the most recog-
nized [46-49]. Furthermore, the importance of the PAG in
the inhibitory system is well characterized in studies with
the administration of DAMGO (a mu-opioid agonist) and
DPDPE (a delta-opioid agonist), which were able to at-
tenuate neuropathic pain symptoms in rats; in contrast,
naloxone (opioid antagonist, administered i.p.) reversed
these effects [49].
Our results confirm and extend previous findings that
locomotion and muscle strength is impaired in the neu-
ropathic pain syndrome [50-53] observed in the CCI mo-
del 14 days post injury. Our results demonstrated that ten
NM sessions restored locomotor dysfunction and muscle
strength associated with the CCI condition. Medinaceli
et al. [27] were the first researchers to describe the sciatic
functional index as a tool to assess the locomotor dysfunc-
tion followed by a sciatic nerve lesion and Wallerian de-
generation [27]. Regarding locomotor dysfunction, our
data demonstrate the effects of NM in improving motor
dysfunction induced by a CCI injury. In addition, the same
group of animals increased maximal tetanic force when
compared to animals without NM treatment. Our data
corroborate studies showing that nerve crush injury
induces locomotor dysfunction due to degeneration of
axons [54-57] and that CCI injury causes Wallerian
degeneration ADDIN EN.CITE [58-60]. Interestingly,
previous studies from our group demonstrated an increase
in myelination and zero protein levels in the sciatic nerve
of CCI rats submitted NM treatment, demonstrating the
regenerative efficiency of this technique [25]. This finding
suggests, once again, that NM it is a good manual tech-
nique to improve pain behavior with neuropathic pain
injury.
Because the literature remains scarce with regard to
scientific studies investigating why and how rehabilita-
tion techniques are able to produce an improvement in
the patient’s condition, we have demonstrated the rela-
tionship between neural mobilization and opioids for the
first time; this procedure has been widely used to treat
clinical syndromes, such as nerve compression, radiculo-
pathy and postsurgical neuropathies [23,61,62].
In summary, the NM technique reverses the deficit in
muscle strength and locomotor dysfunction observed in an
animal model of neuropathic pain. Non-pharmacological
treatment also increases opioid receptor levels in an area
of the brainstem known to be important in pain modula-
tion. These data provide evidence that NM facilitates pain
relief through endogenous analgesic modulation. Clinical
studies in humans have shown that NM reduces neuro-
pathic pain; however, the molecular mechanisms remain
elusive [61-64]. The current findings have significant im-
plications in the clinical rehabilitation of patients with
neuropathic pain.
Despite the efficacy and long-lasting antinociceptive
effect observed in our studies, the possibilities that neu-
ral mobilization may represent an important therapeutic
approach to control chronic pain, should be carefully eval-
uated through future studies.
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